If you have been reading about Aliquot and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
Container selection matters because peptides can adsorb to glass, plastic, and filter membranes. Low-binding polypropylene tubes reduce losses for hydrophobic sequences, and filtration through a 0.22 µm membrane can remove particulates and microorganisms. Some peptides may bind to certain filter materials, so compatibility should be checked. Aliquots should be prepared before freezing to avoid repeated temperature cycling. Labels should record the peptide identity, lot number, solvent, concentration, reconstitution date, and storage condition.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Once reconstituted, a peptide solution is generally less stable than the dry powder. Hydrolysis, oxidation, aggregation, and microbial growth can change the preparation over time, so storage temperature and duration are practical concerns. Dividing a solution into single-use aliquots before freezing can reduce repeated freeze-thaw cycles, which may otherwise cause precipitation or loss of activity. The optimal storage conditions vary by peptide, and no single rule applies to all sequences. Records of solvent, concentration, date, and storage history help maintain traceability. Studies often report stability under defined conditions rather than universal shelf lives.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
| Property | Value | Notes |
|---|---|---|
| Lyophilized storage | −20 °C or below | Sealed container with desiccant limits moisture ingress. |
| Reconstituted storage | 2 to 8 °C short term | Freezing aliquots at −20 °C or below may extend stability for some peptides. |
| Preferred container | Low-binding polypropylene | Reduces adsorption losses compared with untreated glass. |
| Sterilization method | 0.22 µm filtration | Filter material compatibility should be verified for each peptide. |
| Common label data | Peptide, lot, date, concentration | Supports traceability and avoids repeated freeze-thaw cycles. |
Documentation supports reproducibility and traceability. Records often include lot number, solvent composition, final concentration, preparation date, and storage location. Such details help distinguish procedural variation from actual sample instability. Questions remain about how best to predict long-term stability from short-term accelerated studies, because peptide degradation pathways differ widely. For many peptides, the relationship between in vitro solution stability and biological behavior is incompletely understood and is an active area of research.
After reconstitution, a peptide solution is typically stored under conditions that limit degradation. Cool temperatures slow hydrolysis and oxidation, while freezing can preserve samples for longer periods. Repeated freeze-thaw cycles may promote aggregation or precipitation, so aliquoting before freezing is a common laboratory practice. The optimal storage temperature depends on the peptide sequence, buffer composition, and expected duration. Solutions containing oxidizable residues may benefit from inert gas overlays or antioxidants, though compatibility with the specific peptide must be considered.
Quality control of reconstituted peptides combines visual inspection with instrumental analysis. A clear solution does not prove correct identity or purity, and a cloudy solution does not always indicate failure. Reverse-phase high-performance liquid chromatography can separate the peptide from related impurities, while mass spectrometry confirms molecular mass and detects modifications. pH measurement and osmolality checks provide additional information about the solution environment, and documentation of lot number, solvent, and storage history supports traceability.
After a peptide is reconstituted, handling practices affect its chemical and physical stability over time. Aqueous solutions can support microbial growth unless they are prepared with aseptic technique or contain preservatives. Container material matters because peptides can adsorb to glass or plastic surfaces, reducing the amount available in solution. Repeated transfers increase exposure to air and potential contaminants, and temperature fluctuations can accelerate degradation. These factors are separate from the peptide's intrinsic sequence-based stability.
Storage conditions for reconstituted peptides are product-specific. Cool temperatures slow many degradation pathways, but freezing can concentrate solutes and promote aggregation. Light exposure can oxidize susceptible residues such as methionine, cysteine, or tryptophan. Oxygen in headspace can contribute to oxidation, while acidic or basic pH can drive hydrolysis and deamidation. The best storage condition for a given sequence is often determined empirically because general rules do not capture all sequence-specific effects.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
EMP, also known as estradiol normustine phosphate, is a combined estrogen ester and nitrogen mustard ester. It consists of estradiol, an estrogen, linked with a phosphate ester as well as an ester of normustine, a nitrogen mustard. In terms of its pharmacodynamic effects, EMP is a prodrug of estramustine, estromustine, and estradiol. As a prodrug of estradiol, EMP is an estrogen and hence an agonist of the estrogen receptors. EMP itself has only very weak affinity for the estrogen receptors. The medication is of about 91% higher molecular weight than estradiol due to the presence of its C3 normustine and C17β phosphate esters. Because EMP is a prodrug of estradiol, it may be considered to be a natural and bioidentical form of estrogen, although it does have additional cytostatic activity via estramustine and estromustine. EMP acts by a dual mechanism of action: 1) direct cytostatic activity via a number of actions; and 2) as a form of high-dose estrogen therapy via estrogen receptor-mediated antigonadotropic and functional antiandrogenic effects. The antigonadotropic and functional antiandrogenic effects of EMP consist of strong suppression of gonadal androgen production and hence circulating levels of androgens such as testosterone; greatly increased levels of sex hormone-binding globulin and hence a decreased fraction of free androgens in the circulation; and direct antiandrogenic actions in prostate cells. The free androgen index with oral EMP has been found to be on average 4.6-fold lower than with orchiectomy.
The emu has a prominent place in Australian Aboriginal mythology, including a creation myth of the Yuwaalaraay and other groups in New South Wales who say that the sun was made by throwing an emu's egg into the sky; the bird features in numerous aetiological stories told across a number of Aboriginal groups. One story from Western Australia holds that a man once annoyed a small bird, who responded by throwing a boomerang, severing the arms of the man and transforming him into a flightless emu. The Kurdaitcha man of Central Australia is said to wear sandals made of emu feathers to mask his footprints. Many Aboriginal language groups throughout Australia have a tradition that the dark dust lanes in the Milky Way represent a giant emu in the sky. Several of the Sydney rock engravings depict emus, and the birds are mimicked in Indigenous dances. Hunting emus, known as kari in the Kaurna language, features in the major Dreaming story of the Kaurna people of the Adelaide region about the ancestor hero Tjilbruke. The emu is popularly but unofficially considered as a faunal emblem – the national bird of Australia. It appears as a shield bearer on the Coat of arms of Australia with the red kangaroo, and as a part of the Arms also appears on the Australian 50-cent coin. It has featured on numerous Australian postage stamps, including a pre-federation New South Wales 100th Anniversary issue from 1888, which featured a 2 pence blue emu stamp, a 36-cent stamp released in 1986, and a $1.35 stamp released in 1994.
2-hydroxyisoflavanone synthase (EC 1.14.14.87, CYT93C, IFS, isoflavonoid synthase) is an enzyme with systematic name liquiritigenin,NADPH:oxygen oxidoreductase (hydroxylating, aryl migration). It catalyses a rearrangement reaction which converts flavonoids into isoflavones, for example:
Somali is the official language of Somalia and Arabic is the second language. The Somali language is the mother tongue of the Somali people, the most populous ethnic group. It the best documented member of the Cushitic branch of the Afro-Asiatic language family. Somali dialects are divided into Northern, Benadir and Maay. Northern Somali is the basis for Standard Somali. Benadir is spoken on the Benadir coast, being the most spoken dialect. The coastal dialects have additional phonemes that absent in Standard Somali. Maay is principally spoken by the Rahanweyn clan in south. Many writing systems have been used for Somali. Of these, the Somali alphabet is the most widely used, being the official writing script since the Supreme Revolutionary Council introduced it in 1972. Other orthographies that have been used for centuries for writing Somali include the long-established Arabic script and Wadaad's writing.
== Ownership and finance == Marks and Hazan initially supported GYG with their own money. In 2009, they sold a minority stake to Peter Ritchie, Guy Russo and Steve Jermyn, who had previously been involved with McDonald's Australia. Russo was subsequently appointed chairman of the board. The board also includes co-founder Robert Hazan, Tom Cowan of TDM Growth Partners, Rokt CEO Bruce Buchanan, and three former McDonalds executives. Investment firm TDM Growth Partners bought a stake in the company for $44 million in August 2018. In December 2020, the publicly listed Magellan Financial Group bought 10% of the company for $86.8 million. In May 2022, Magellan sold its 11.6% stake in the company to an entity owned by investment bank Barrenjoey Capital Partners for $140 million. Marks stated in 2019 that his goal was to list GYG on the Australian Securities Exchange. In 2020, he stated that he was also ambitious to expand the company's presence in the United States, citing Australia's "antiquated" labour laws, high rents, and expensive fresh produce. Marks resigned as CEO due to a health scare in May 2023, but he changed his mind and remained. Hilton Brett was appointed co-CEO in October 2023. GYG was listed on the Australian Securities Exchange on 20 June 2024.
Sources: en.wikipedia.org
== Toxicity rates == In earlier years it was thought that apamin was a rather nontoxic compound (LD50 = 15 mg/kg in mice) compared to the other compounds in bee venom. The current lethal dose values of apamin measured in mice are given below. There are no data known specific for humans. Intraperitoneal (mouse) LD50: 3.8 mg/kg Subcutaneous (mouse) LD50: 2.9 mg/kg Intravenous (mouse) LD50: 4 mg/kg Intracerebral (mouse) LD50: 1800 ng/kg Parenteral (mouse) LD50: 600 mg/kg
== Mechanism of action == An average dairy cow begins her lactation with a moderate daily level of milk production. This daily output increases until, at about 70 days into the lactation, production peaks. From that time until the cow is dry, production slowly decreases. This increase and decrease in production is partially caused by the count of milk-producing cells in the udder. Cell counts begin at a moderate number, increase during the first part of the lactation, then decrease as the lactation proceeds. Once lost, these cells generally do not regrow until the next lactation. Administration of rBST or BST prior to peak production, in cows that are well-fed, slows the rate at which the number of mammary cells decreases, and increases the amount of nutrients directed away from fat and toward the mammary cells, leading to an extension of peak milk production. The effects are mediated by the insulin-like growth factor (IGF) system, which is upregulated in response to BST or rBST administration in well-fed cows.
=== External proton gradient model === Biochemist Nick Lane has proposed the following hypothesis. Deep-sea hydrothermal vents, emitting hot acidic or alkaline water, would have created external proton gradients. These provided energy that primordial organisms could have exploited. To keep the flows separate, such an organism could have wedged itself in the rock of the hydrothermal vent, exposed to the hydrothermal flow on one side and the more alkaline water on the other. As long as the organism's membrane (or passive ion channels within it) is permeable to protons, the mechanism can function without ion pumps. Such a proto-organism could then have evolved further mechanisms such as ion pumps and ATP synthase.
==== Breast-filler toxicity ==== Biological risks to the health of a sucking infant arise from the possibility of breast-filler toxicity, that the filler-material (saline solution or silicone gel) might leak from the breast-implant into the body of the mother, then into her breast milk, and then into the infant organism; yet the biological risk to the breastfeeding infant is minimal, because silicone is indigestible and saline-solution is digestible. The study Silicone Breast Implants and Breastfeeding (1996) indicated that possible medical complications that impede breastfeeding can arise among women with silicone-filled prosthetic breasts, and found no causal relation between the presence of breast prostheses and neurological and physical impairment of the breastfeeding function of the augmented breasts.
== Causes == NMS is usually caused by antipsychotic drug use, but other dopaminergic blocking drugs can also be a cause. Individuals using butyrophenones (such as haloperidol and droperidol) or phenothiazines (such as promethazine and chlorpromazine) are reported to be at greatest risk. However, various atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, and ziprasidone have also been implicated in cases. NMS may also occur in people taking dopaminergic drugs (such as levodopa) for Parkinson's disease, most often when the drug dosage is abruptly reduced. In addition, other drugs with anti-dopaminergic activity, such as the antiemetic metoclopramide, can induce NMS. Tetracyclics with anti-dopaminergic activity have been linked to NMS in case reports, such as the amoxapines. Additionally, desipramine, dothiepin, phenelzine, tetrabenazine, and reserpine have been known to trigger NMS. Whether lithium can cause NMS is unclear. However, concomitant use of lithium is associated with a higher risk of NMS when a person starts on an antipsychotic drug. At the molecular level, NMS is caused by a sudden, marked reduction in dopamine activity, either from withdrawal of dopaminergic agents or blockade of dopamine receptors.
Sources: en.wikipedia.org
Short-term storage is often at 2 to 8 °C, while longer storage may use frozen aliquots at −20 °C or below. Repeated freeze-thaw cycles should be avoided because they can promote aggregation.
Cloudiness may indicate incomplete dissolution, aggregation, or precipitation. Gentle mixing, pH adjustment, or filtration can sometimes resolve it, but the cause should be identified before use.
Bacteriostatic water contains a preservative that can interfere with some assays or react with certain peptides. Sterile water or a defined buffer may be preferable depending on the downstream application.
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.